L C Walker

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Proteopathy: the next therapeutic frontier?
    Lary C Walker
    CNS Pharmacology, Pfizer Ann Arbor Laboratories, MI 48105, USA
    Curr Opin Investig Drugs 3:782-7. 2002
  2. ncbi request reprint Modeling Alzheimer's disease and other proteopathies in vivo: is seeding the key?
    L C Walker
    CNS Pharmacology, Pfizer Ann Arbor Laboratories, Ann Arbor, Michigan 48105, USA
    Amino Acids 23:87-93. 2002
  3. ncbi request reprint Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice
    Lary C Walker
    CNS Pharmacology, Pfizer Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Peptides 23:1241-7. 2002
  4. pmc Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice
    M J Callahan
    Neuroscience Therapeutics, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA
    Am J Pathol 158:1173-7. 2001
  5. ncbi request reprint Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice
    M D Kane
    Neuroscience Therapeutics, Parke Davis Research, Division of Warner Lambert, Ann Arbor, Michigan 48105, USA
    J Neurosci 20:3606-11. 2000
  6. ncbi request reprint Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly
    L C Walker
    Neuroscience Therapeutics, Parke Davis Pharmaceutical Research, Division of Warner Lambert, Ann Arbor, MI 48105, USA
    Acta Neuropathol 100:36-42. 2000
  7. ncbi request reprint Animal models of cerebral beta-amyloid angiopathy
    L C Walker
    Parke Davis Pharmaceutical Research, Division of Warner Lambert, Ann Arbor, MI 48105, USA
    Brain Res Brain Res Rev 25:70-84. 1997
  8. ncbi request reprint Cerebrovascular amyloidosis: experimental analysis in vitro and in vivo
    L C Walker
    Parke Davis Pharmaceutical Research Division, Warner Lambert Co, Ann Arbor, MI 48105, USA
    Histol Histopathol 14:827-37. 1999
  9. pmc Cerebral lipid deposition in aged apolipoprotein-E-deficient mice
    L C Walker
    Department of Neurological and Neurodegenerative Disorders, Division of Warner Lambert Co, Ann Arbor, Michigan 48105, USA
    Am J Pathol 151:1371-7. 1997
  10. pmc Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are regulated tissue-specifically
    Cansu Agca
    University of Missouri College of Veterinary Medicine, Department of Veterinary Pathobiology Columbia, MO 65211, USA
    BMC Neurosci 9:28. 2008

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Proteopathy: the next therapeutic frontier?
    Lary C Walker
    CNS Pharmacology, Pfizer Ann Arbor Laboratories, MI 48105, USA
    Curr Opin Investig Drugs 3:782-7. 2002
    ..Our present knowledge suggests three broad therapeutic approaches to abrogating the proteopathic cascade: reduce the production of the offending proteins, prevent their self-assembly, or promote their removal...
  2. ncbi request reprint Modeling Alzheimer's disease and other proteopathies in vivo: is seeding the key?
    L C Walker
    CNS Pharmacology, Pfizer Ann Arbor Laboratories, Ann Arbor, Michigan 48105, USA
    Amino Acids 23:87-93. 2002
    ....
  3. ncbi request reprint Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice
    Lary C Walker
    CNS Pharmacology, Pfizer Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Peptides 23:1241-7. 2002
    ..The AD-seeding model can illuminate the emergence and spread of cerebral beta-amyloidosis and tau hyperphosphorylation, and thus could enhance our understanding of AD and its pathogenic commonalties with other cerebral proteopathies...
  4. pmc Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice
    M J Callahan
    Neuroscience Therapeutics, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA
    Am J Pathol 158:1173-7. 2001
    ..These data show that senescent female Tg2576 mice deposit more amyloid in the brain than do male mice, and may provide an animal model in which the influence of sex differences on cerebral amyloid pathology can be evaluated...
  5. ncbi request reprint Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice
    M D Kane
    Neuroscience Therapeutics, Parke Davis Research, Division of Warner Lambert, Ann Arbor, Michigan 48105, USA
    J Neurosci 20:3606-11. 2000
    ..The paradigm can be used to clarify the conditions that initiate in vivo beta-amyloidogenesis in the brain and may yield a more authentic animal model of Alzheimer's disease and other neurodegenerative disorders...
  6. ncbi request reprint Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly
    L C Walker
    Neuroscience Therapeutics, Parke Davis Pharmaceutical Research, Division of Warner Lambert, Ann Arbor, MI 48105, USA
    Acta Neuropathol 100:36-42. 2000
    ..We conclude that ApoEepsilon4 hastens the onset of Abeta42 deposition in the senescent brain, which in turn fosters the earlier evolution of fibrillar, Abeta40-positive plaques, thereby increasing the risk of Alzheimer's disease...
  7. ncbi request reprint Animal models of cerebral beta-amyloid angiopathy
    L C Walker
    Parke Davis Pharmaceutical Research, Division of Warner Lambert, Ann Arbor, MI 48105, USA
    Brain Res Brain Res Rev 25:70-84. 1997
    ..The existing animal models have shown considerable utility in deciphering the pathobiology of CAA, and in testing strategies that could be used to diagnose and treat this disorder in humans...
  8. ncbi request reprint Cerebrovascular amyloidosis: experimental analysis in vitro and in vivo
    L C Walker
    Parke Davis Pharmaceutical Research Division, Warner Lambert Co, Ann Arbor, MI 48105, USA
    Histol Histopathol 14:827-37. 1999
    ..Methods for delivering agents selectively to vascular amyloid in living subjects are now being developed, and these techniques are paving the way to the development of diagnostic tools and therapies for cerebrovascular amyloidosis...
  9. pmc Cerebral lipid deposition in aged apolipoprotein-E-deficient mice
    L C Walker
    Department of Neurological and Neurodegenerative Disorders, Division of Warner Lambert Co, Ann Arbor, Michigan 48105, USA
    Am J Pathol 151:1371-7. 1997
    ..It may be fruitful to seek potential interactions between genetic factors and diet in modulating the risk of Alzheimer's disease and other neurodegenerative disorders in aged humans...
  10. pmc Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are regulated tissue-specifically
    Cansu Agca
    University of Missouri College of Veterinary Medicine, Department of Veterinary Pathobiology Columbia, MO 65211, USA
    BMC Neurosci 9:28. 2008
    ..Some instances of FAD have been linked to mutations in the beta-amyloid protein precursor (APP). Although there are numerous mouse AD models available, few rat AD models, which have several advantages over mice, have been generated...
  11. pmc Tauopathy with paired helical filaments in an aged chimpanzee
    Rebecca F Rosen
    Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30329, USA
    J Comp Neurol 509:259-70. 2008
    ....
  12. ncbi request reprint Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host
    Melanie Meyer-Luehmann
    Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, D 72076 Tubingen, Germany
    Science 313:1781-4. 2006
    ..The phenotype of the exogenously induced amyloidosis depended on both the host and the source of the agent, suggesting the existence of polymorphic Abeta strains with varying biological activities reminiscent of prion strains...
  13. ncbi request reprint Inducible proteopathies
    Lary C Walker
    Yerkes National Primate Research Center and Department of Neurology, Emory University, Atlanta, GA 30322, USA
    Trends Neurosci 29:438-43. 2006
    ....
  14. ncbi request reprint Emerging prospects for the disease-modifying treatment of Alzheimer's disease
    Lary C Walker
    Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30322, USA
    Biochem Pharmacol 69:1001-8. 2005
    ..These adverse events were not anticipated from preclinical studies with rodents; hence, more biologically relevant models, such as nonhuman primates, are needed to test the safety and efficacy of novel therapies for Alzheimer's disease...
  15. pmc Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease
    Jens Pahnke
    University of Rostock, Department of Neurology, Neurodegeneration Research Laboratory NRL, Gehlsheimer Str 20, 18147 Rostock, Germany
    Curr Alzheimer Res 5:396-405. 2008
    ..Here, we summarize findings from cell culture experiments, animal models and studies of patients with Alzheimer's disease. Furthermore, we discuss pharmacological interactions and computational methods for risk assessment...
  16. ncbi request reprint Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits
    Jun Yao
    Department of Psychiatry, New York University, The Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York, USA
    J Neurochem 90:1011-8. 2004
    ....
  17. ncbi request reprint Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice
    Feng Bian
    CNS Pharmacology, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Comp Neurol 446:257-66. 2002
    ....
  18. doi request reprint Long-term hypothermia reduces infarct volume in aged rats after focal ischemia
    Baltromejus Florian
    Department of Neurology, University of Greifswald, Ellernholzstr 1 2, 17487 Greifswald, Germany
    Neurosci Lett 438:180-5. 2008
    ..Conclusions: Prolonged, H(2)S-induced hypothermia is a simple and efficacious method to limit the damage inflicted by stroke in aged rats...
  19. ncbi request reprint Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans
    Silke Vogelgesang
    Departments of Neuropathology and Pharmacology, Peter Holtz Research Center of Pharmacology and Experimental Therapeutics, University of Greifswald, Greifswald, Germany
    Pharmacogenetics 12:535-41. 2002
    ..Our results provide the first evidence in human brain tissue that the accumulation of Abeta may be influenced by the expression of P-gp in blood vessels, and suggest that P-gp may influence the elimination of Abeta from brain...
  20. ncbi request reprint The response of the aged brain to stroke: too much, too soon?
    Aurel Popa-Wagner
    Department of Neurology, University of Greifswald, Greifswald, Germany
    Curr Neurovasc Res 4:216-27. 2007
    ..Elucidating the molecular basis of this phenomenon in the aging brain could yield novel approaches to neurorestoration following stroke or head injury in the elderly...
  21. ncbi request reprint MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier
    Diana Kuhnke
    Department of Pharmacology, Research Center of Pharmacology and Experimental Therapeutics, Ernst Moritz Arndt University, Greifswald, Germany
    Brain Pathol 17:347-53. 2007
    ..Our data support the concept that P-gp is important for the clearance of Abeta from brain, and thus may represent a target protein for the prevention and/or treatment of neurodegenerative disorders such as AD...
  22. ncbi request reprint Alzheimer's Abeta vaccination of rhesus monkeys (Macaca mulatta)
    Sam Gandy
    Farber Institute for Neurosciences, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Mech Ageing Dev 125:149-51. 2004
    ..These data support the use of non-human primates to model certain phenomena associated with vaccination of humans with aggregated Alzheimer's Abeta...
  23. ncbi request reprint Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta)
    Sam Gandy
    Farber Institute for Neurosciences, Thomas Jefferson University, 900 Walnut St, Suite 467, Philadelphia, PA 19107, USA
    Alzheimer Dis Assoc Disord 18:44-6. 2004
    ..These data support the use of nonhuman primates to model certain phenomena associated with vaccination of humans with aggregated Alzheimer A beta...
  24. ncbi request reprint Alzheimer therapeutics-what after the cholinesterase inhibitors?
    Lary C Walker
    Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322, USA
    Age Ageing 35:332-5. 2006
  25. ncbi request reprint Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease
    Silke Vogelgesang
    Department of Neuropathology, University of Greifswald, 17487, Greifswald, Germany
    Acta Neuropathol 111:436-43. 2006
    ....
  26. pmc The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease
    Silke Vogelgesang
    Department of Neuropathology, University of Greifswald, Germany
    Curr Alzheimer Res 1:121-5. 2004
    ..The impairment of Abeta clearance could lead to the accumulation and earlier deposition of Abeta, both in the walls of blood vessels and in the brain parenchyma, thus elevating the risk of CAA and AD...
  27. ncbi request reprint Proteomic identification of the involvement of the mitochondrial rieske protein in epilepsy
    Heike Junker
    Institutes of Biochemistry, Ernst Moritz Arndt University, Greifswald, Germany
    Epilepsia 46:339-43. 2005
    ....